BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2017; 23(31): 5650-5668 [PMID: 28883691 DOI: 10.3748/wjg.v23.i31.5650] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Perillo A, Agbaje Olufemi MV, De Robbio J, Mancuso RM, Roscigno A, Tirozzi M, Scognamiglio IR. Liquid biopsy in NSCLC: a new challenge in radiation therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00038] [Reference Citation Analysis]
2 Bhan I, Haber DA, Chung RT, Ting DT. Liquid Biopsy in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 125-41. [DOI: 10.1007/978-3-030-21540-8_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Sun L, Zhang Y, Zhang W, Lai X, Li Q, Zhang L, Sun S. Green tea and black tea inhibit proliferation and migration of HepG2 cells via the PI3K/Akt and MMPs signalling pathway. Biomedicine & Pharmacotherapy 2020;125:109893. [DOI: 10.1016/j.biopha.2020.109893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
4 Tan P, Grundy L, Makary P, Eng KH, Ramsay G, Bekheit M. The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review. Transl Gastroenterol Hepatol 2021;6:54. [PMID: 34805576 DOI: 10.21037/tgh.2020.01.11] [Reference Citation Analysis]
5 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
6 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yin LC, Luo ZC, Gao YX, Li Y, Peng Q, Gao Y. Twist Expression in Circulating Hepatocellular Carcinoma Cells Predicts Metastasis and Prognoses. Biomed Res Int 2018;2018:3789613. [PMID: 30046595 DOI: 10.1155/2018/3789613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
8 Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
9 Xie S, Jiang X, Zhang J, Xie S, Hua Y, Wang R, Yang Y. Identification of significant gene and pathways involved in HBV-related hepatocellular carcinoma by bioinformatics analysis. PeerJ 2019;7:e7408. [PMID: 31392101 DOI: 10.7717/peerj.7408] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
10 Long G, Fang T, Su W, Mi X, Zhou L. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scand J Gastroenterol 2020;55:1441-6. [PMID: 33119422 DOI: 10.1080/00365521.2020.1839127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Zhou KQ, Sun YF, Cheng JW, Du M, Ji Y, Wang PX, Hu B, Guo W, Gao Y, Yin Y, Huang JF, Zhou J, Fan J, Yang XR. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine 2020;62:103107. [PMID: 33181461 DOI: 10.1016/j.ebiom.2020.103107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Alunni-Fabbroni M, Rönsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, Pech M, Basu B, Verslype C, Benckert J, Malfertheiner P, Ricke J. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med 2019;17:328. [PMID: 31570105 DOI: 10.1186/s12967-019-2079-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
14 Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598-609. [PMID: 30039640 DOI: 10.1111/apt.14913] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 15.8] [Reference Citation Analysis]
15 Raos D, Ulamec M, Katusic Bojanac A, Bulic-Jakus F, Jezek D, Sincic N. Epigenetically inactivated RASSF1A as a tumor biomarker. Bosn J Basic Med Sci 2021;21:386-97. [PMID: 33175673 DOI: 10.17305/bjbms.2020.5219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hung YP, Shao YY, Hsu C, Hsu CH, Lee JM, Yang MH, Chao Y. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. J Formos Med Assoc 2021;120:1581-90. [PMID: 33334658 DOI: 10.1016/j.jfma.2020.11.015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Reference Citation Analysis]
18 Wei F, Yang L, Jiang D, Pan M, Tang G, Huang M, Zhang J. Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR-422a/PDK2 axis. Cancer Med 2020;9:2480-90. [PMID: 32022476 DOI: 10.1002/cam4.2861] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
19 Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020;155:103109. [PMID: 33049662 DOI: 10.1016/j.critrevonc.2020.103109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Li N, Li L, Chen Y. The Identification of Core Gene Expression Signature in Hepatocellular Carcinoma. Oxid Med Cell Longev. 2018;2018:3478305. [PMID: 29977454 DOI: 10.1155/2018/3478305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
21 Wu S, Ai H, Zhang K, Yun H, Xie F. Long Non-Coding RNA EGOT Promotes the Malignant Phenotypes of Hepatocellular Carcinoma Cells and Increases the Expression of HMGA2 via Down-Regulating miR-33a-5p. Onco Targets Ther 2019;12:11623-35. [PMID: 32021242 DOI: 10.2147/OTT.S218308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Chen Y, Xie H, Xie T, Yang X, Pang Y, Ye S. Elevated Expression of PDZD11 Is Associated With Poor Prognosis and Immune Infiltrates in Hepatocellular Carcinoma. Front Genet 2021;12:669928. [PMID: 34093661 DOI: 10.3389/fgene.2021.669928] [Reference Citation Analysis]
23 Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
24 Carissimi F, Barbaglia MN, Salmi L, Ciulli C, Roccamatisi L, Cordaro G, Mallela VR, Minisini R, Leone BE, Donadon M, Torzilli G, Pirisi M, Romano F, Famularo S. Finding the seed of recurrence: Hepatocellular carcinoma circulating tumor cells and their potential to drive the surgical treatment. World J Gastrointest Surg 2021; 13(9): 967-978 [PMID: 34621473 DOI: 10.4240/wjgs.v13.i9.967] [Reference Citation Analysis]
25 Luo Q, Wang C, Peng B, Pu X, Cai L, Liao H, Chen K, Zhang C, Cheng Y, Pan M. Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma. Front Oncol. 2020;10:1758. [PMID: 33224869 DOI: 10.3389/fonc.2020.01758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Yang WY, Feng LF, Meng X, Chen R, Xu WH, Hou J, Xu T, Zhang L. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes. Expert Rev Mol Diagn 2020;20:1213-27. [PMID: 33232189 DOI: 10.1080/14737159.2020.1855977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 He K, Zhang S, Shao LL, Yin JC, Wu X, Shao YW, Yuan S, Yu J. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Lett 2020;472:108-18. [PMID: 31837443 DOI: 10.1016/j.canlet.2019.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Su YH, Kim AK, Jain S. Liquid biopsies for hepatocellular carcinoma. Transl Res 2018;201:84-97. [PMID: 30056068 DOI: 10.1016/j.trsl.2018.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
29 Kudou M, Kosuga T, Otsuji E. Artificial intelligence in gastrointestinal cancer: Recent advances and future perspectives. Artif Intell Gastroenterol 2020; 1(4): 71-85 [DOI: 10.35712/aig.v1.i4.71] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wu X, Li J, Gassa A, Buchner D, Alakus H, Dong Q, Ren N, Liu M, Odenthal M, Stippel D, Bruns C, Zhao Y, Wahba R. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci 2020;16:1551-62. [PMID: 32226301 DOI: 10.7150/ijbs.44024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
31 Elzehery R, Effat N, El Farahaty R, Elsayed Farag R, Abo-Hashem EM, Elhelaly R. Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma. Am J Clin Pathol 2022:aqac037. [PMID: 35403666 DOI: 10.1093/ajcp/aqac037] [Reference Citation Analysis]
32 Barrera-Saldaña HA, Fernández-Garza LE, Barrera-Barrera SA. Liquid biopsy in chronic liver disease. Ann Hepatol 2021;20:100197. [PMID: 32444248 DOI: 10.1016/j.aohep.2020.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Espejo-Cruz ML, González-Rubio S, Zamora-Olaya J, Amado-Torres V, Alejandre R, Sánchez-Frías M, Ciria R, De la Mata M, Rodríguez-Perálvarez M, Ferrín G. Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. Int J Mol Sci 2021;22:13073. [PMID: 34884878 DOI: 10.3390/ijms222313073] [Reference Citation Analysis]
34 Mann J, Reeves HL, Feldstein AE. Liquid biopsy for liver diseases. Gut 2018;67:2204-12. [PMID: 30177542 DOI: 10.1136/gutjnl-2017-315846] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
35 Pelizzaro F, Cardin R, Penzo B, Pinto E, Vitale A, Cillo U, Russo FP, Farinati F. Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now? Cancers (Basel) 2021;13:2274. [PMID: 34068786 DOI: 10.3390/cancers13092274] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Bratulic S, Gatto F, Nielsen J. The Translational Status of Cancer Liquid Biopsies. Regen Eng Transl Med . [DOI: 10.1007/s40883-019-00141-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
37 Rodríguez J, Avila J, Rolfo C, Ruíz-Patiño A, Russo A, Ricaurte L, Ordóñez-Reyes C, Arrieta O, Zatarain-Barrón ZL, Recondo G, Cardona AF. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther 2021;9:89-110. [PMID: 33689160 DOI: 10.1007/s40487-021-00144-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Li L, Zhao H, Chen B, Huang K, Hao Z, Fan Z, Sun G, Wu J, Li N, Ye Q, Yue J. Noninvasive Identification of Immune-Related Biomarkers in Hepatocellular Carcinoma. J Oncol 2019;2019:2531932. [PMID: 31531018 DOI: 10.1155/2019/2531932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293 [PMID: 31148900 DOI: 10.3748/wjg.v25.i19.2279] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
40 Zhang Y, Yang Y, Zhang Y, Liu Z. lncRNA ST8SIA6-AS1 facilitates proliferation and invasion in liver cancer by regulating miR-142-3p. Exp Ther Med 2021;22:1348. [PMID: 34659494 DOI: 10.3892/etm.2021.10783] [Reference Citation Analysis]
41 Tsuchiya A, Ogawa M, Watanabe T, Takeuchi S, Kojima Y, Watanabe Y, Kimura N, Hayashi K, Yokoyama J, Terai S. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma. Heliyon 2019;5:e01325. [PMID: 30911692 DOI: 10.1016/j.heliyon.2019.e01325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2018;129:44-53. [DOI: 10.1016/j.critrevonc.2018.06.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
43 Kong D, Zhang W, Yang Z, Li G, Cheng S, Zhang K, Feng L. Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis. Oncoimmunology 2021;10:1938476. [PMID: 34211802 DOI: 10.1080/2162402X.2021.1938476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Zhang Q, Lou Y, Bai XL, Liang TB. Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. World J Gastroenterol 2020; 26(26): 3720-3736 [PMID: 32774053 DOI: 10.3748/wjg.v26.i26.3720] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther 2020;20:63-74. [PMID: 31910040 DOI: 10.1080/14737140.2020.1712198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
46 Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:114. [PMID: 31269959 DOI: 10.1186/s12943-019-1043-x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 22.0] [Reference Citation Analysis]
47 Ameri M, Salimi H, Eskandari S, Nezafat N. Identification of potential biomarkers in hepatocellular carcinoma: A network-based approach. Informatics in Medicine Unlocked 2022. [DOI: 10.1016/j.imu.2022.100864] [Reference Citation Analysis]
48 Temraz S, Nasr R, Mukherji D, Kreidieh F, Shamseddine A. Liquid Biopsy Derived Circulating Tumor Cells and Circulating Tumor DNA as Novel Biomarkers in Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35758097 DOI: 10.1080/14737159.2022.2094706] [Reference Citation Analysis]
49 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 58.0] [Reference Citation Analysis]
50 Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Higaki S, Fujii I, Suzuki C, Shindo Y, Tokumitsu Y, Nagano H, Sakaida I, Yamasaki T. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun 2020;4:461-70. [PMID: 32140662 DOI: 10.1002/hep4.1469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]